June 27, 2022 8:03am

As quarter-end rebalancing could lead to a buying spree in equities

Have we found a true bottom, not yet?

Pre-open indications, 1 Negative Indications, 3 Positive Indications and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.36% (+109 points), S&P futures are UP +0.49% (+19 points) and NASDAQ futures are UP +0.64% (+78 points) early in the pre-open – so far,

 

U.S. stock futures rose on Monday morning,

European stocks moved higher,

Asia-Pacific stocks also traded higher.

 

Henry’omics:

Indexes continued higher on Friday, on track for strong weekly gains led by the Nasdaq.

The Dow closed UP +826.35 points (+2.69%); the S&P closed UP +116.42 points (+3.07%) while the Nasdaq closed UP +375.43 points (+3.34%)

This week's “rebalance is important since equity markets were down significantly over the past month, quarter and six-month time periods, and it is happening in a period of low liquidity. On top of that, the market is in an oversold condition, cash balances are at record levels, and recent market shorting activity reached levels not seen since 2008," JPMorgan's Marko Kolanovic <Business Insider>

The major indexes rebounded after fierce losses for much of the month. It was the best week for the Nasdaq since mid-March, while the S&P 500 and Dow had their best week since the last full week of May. Keep in mind that after that late May bounce, the market moved sideways for several sessions before plunging to new lows. <IBD>

 

RegMed Investors’ (RMi) closing bell: “cell and gene therapy sector gets a spanking as investors exit upcoming and present risks” … https://www.regmedinvestors.com/articles/12488

Ebb and flow –

Q2/22 –

June – 9 positive and 8 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes

Q1/22:

·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indications:

Verve Therapeutics (VERV) closed up +$0.72 to $16.90 after Thursday’s +$2.08 after Wednesday’s $1.07 with a negative -$0.51 or -3.02% pre-open indication,

 

Positive Indication:

Beam Therapeutics (BEAM) closed up+$0.94 to $42.51 after Thursday’s -$2.44 with a positive +0.36 or +0.85% pre-open indication,

CRISPR Therapeutics (CRSP) closed up +$1.81 to $66.96 <52-week low of $42.51> with a positive +$0.84 or +1.25% pre-open indication,

Alnylam Pharmaceuticals (ALNY) closed up +$1.20 to $147.50 after Thursday’s +$4.74, Wednesday’s +$2.54 and last Tuesday’s +$1.93 with a positive +$0.45 or +0.31% pre-open indication,

 

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed $0.00 to $4.30 with 0 shares traded after Thursday’s -$0.09 with 100 shares traded following Wednesday $0.00 after Tuesday’s +$0.09 with 467 shares traded.

WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors.

BSTG filed a new 8-K re Harvard BIOSCIENCE  (HBIO) and in lieu of cash payment < https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=116769338&type=HTML&formType=8-K&dateFiled=2022-06-13&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage >

BSTG seems to always finagling a finagle and NOTHING is CLEAN and STRAIGHTFORWARD.

 is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements

 

The BOTTOM LINE: Whay nreally changes ...?

On Friday, all the major indexes had big price gains in a broad, powerful advance. Volume, which was running slightly lower on the Nasdaq and NYSE for most of the session, skyrocketed at the close thanks to the annual Russell rebalancing.

The Nasdaq umped above its 21-day moving average on Friday, along with the Dow Jones and S&P 500. Above that, the 50-day line and early June highs loom as resistance.

There will be a few pick-up stocks – remember, the month and quarter are coming to a close – earnings are coming …

Investors may want to at least consider taking partial profits – when they can; we are approaching earnings season, no sooner did we finish than we start again.

I STILL haven’t heard the bugle sound of a sustainable advance or rally … rising rates and slowing economic growth are not a supportive environment for investors.

This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

I have NOT seen ANY step-up of declining company investments by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.